Michael Dempsey

Who they are

Michael Dempsey is Managing Partner at Compound — built his investing lens through CB Insights and Crane Partners before co-founding the firm in 2016, with theses spanning AI/ML, robotics, crypto, and healthcare.

Person

Michael joined Compound in September 2016, founding it essentially from scratch out of New York. Before that he was at Crane Partners doing multi-asset-class early-stage technology investing, and before that at CB Insights on the research and data analysis team — a path that goes data-first, then investing, then firm-building. A BA from New York University anchors his formation in New York, and he's stayed. The through-line is moving from understanding markets analytically to taking positions in them, eventually owning the vehicle entirely. His stated content themes — crypto, AI/ML, robotics, healthcare/bio — signal a generalist early-stage thesis with a bias toward technical and science-heavy companies. Possibly — his CB Insights background shapes how he thinks about market sizing and competitive dynamics, since that's a firm built on making those calls systematically.

Company

Compound's most recent financing activity is a Seed round closed in April 2026, with two investors participating. Prior to that, Compound raised $37.6M in November 2022, and across its full history has brought in $58M from backers including Greenoaks Capital, Accel, Lachy Groom, and Basis Set Ventures. The firm is based in New York and operates in early-stage technology investing.

Market

Compound competes with other firms in the fintech and early-stage venture space. The broader investment environment in 2025–2026 is being shaped by increasing regulatory scrutiny on deals and geopolitical forces — factors that affect portfolio company M&A timelines and the global trade context that early-stage founders have to operate within.

How they likely show up

  • Long tenure at Compound since September 2016 → likely thinks in multi-year conviction cycles, not quarter-to-quarter momentum.
  • Started at CB Insights in data/research before moving to investing → probably brings a structured, evidence-first approach to thesis formation rather than pure pattern-matching.
  • Content themes span crypto, AI/ML, robotics, and healthcare/bio — four distinct technical verticals → likely reads across domains and gets impatient with shallow takes on any one of them.
  • Role type pattern is 'investor' across both Crane Partners and Compound → consistent identity as a capital allocator, not an operator who pivoted to VC.
  • Based in New York throughout career → embedded in the NY tech and finance ecosystem rather than the SF consensus.

Conversation tips

  • → Lead with a specific technical or market insight — his CB Insights background means he'll immediately test whether you've done the underlying research.
  • → Don't treat his thesis areas as separate silos; he covers crypto, AI/ML, robotics, and healthcare simultaneously, so cross-domain pattern observations will land well.
  • → Ask about firm-building, not just deal-making — he's been at Compound since 2016 and has managed its full lifecycle through multiple funding rounds.
  • → Avoid VC-generic talking points about 'the market right now' — he thinks in longer arcs and will likely redirect to fundamentals.
  • → Reference the New York angle: his firm is NY-based in a sector often dominated by SF perspectives, which is likely a deliberate positioning choice worth exploring.

Toolbox

Openers

  • Open on Compound's April 2026 Seed close — a fresh financing event with two investors is an unusual structure for a VC firm and gives you a natural reason to ask what's being built or rebuilt right now.
  • Reference his CB Insights roots — he came to investing through data and market research, which is an unusual entry point; noting that specifically signals you understand his analytical orientation rather than treating him as a generic VC.
  • His content themes list robotics alongside crypto and AI — that combination is less common than pure software bets, and opening on a robotics or bio thesis observation would immediately differentiate the conversation.

Discovery questions

  1. You came to investing through CB Insights' research function — how much does that data-first background still shape how you stress-test a new thesis today?
  2. Compound has backed companies across crypto, AI/ML, robotics, and healthcare — when those verticals start converging in a single company, does that make it more or less interesting to you?
  3. The April 2026 Seed round is a notable structure for a firm at your stage — what does that financing moment represent for where Compound is heading next?

Avoid

Don't open with generic venture market commentary about 'the current funding environment' — his career has been built on original research and conviction, and surface-level macro takes will signal you haven't done the work.

Make it yours

Tailor these openers to what you sell

These openers are generic. Sign in and tell Brief what you sell — it rewrites the hooks and questions around your pitch.

Sources

Brief on your next meeting?

Type any name. Get a structured pre-meeting brief in seconds.

Try Brief →

Generated by briefthecall.com from public web sources on June 5, 2026. Each claim is linked to its source above.

Automatically generated by AI from public sources. May be inaccurate or out of date. Remove or correct this profile →